The company plans to raise money this fall to support the continued development of its head-and-neck cancer testing platform and oral squamous cell carcinoma test.

The firm said that the reverse split is intended to help the company to regain compliance with the Nasdaq's $1.00 per share minimum bid price requirement.

The company's clinical chemistry test uses the NGAL biomarker to determine a patient's risk of acute kidney injury.

Proscia has integrated its Concentriq platform with AWS HealthImaging to provide a cloud-native foundation for pathology.

Last week, readers were most interested in a story about a possible sale of Siemens Healthineer's IVD business, leading to an uptick in the company's share price.

Under the agreement, Tempus and Renalytix will work with US healthcare systems to make the KidneyintelX.dkd test more available to order within existing clinical workflows.

Titled the RESULTS Act, the bill would use third-party private-payor data to set Medicare lab payment rates, addressing a ...

The program is intended to advance the development of antigen tests that can be used in homes and at the point-of-care to aid the detection of dangerous infections.

The submitted test runs on the firm's point-of-care instrument and detects four respiratory pathogens within 10 minutes directly from patient nasal swab samples.

The scientists said that the test could help clinicians overcome a lack of specificity in prostate-specific antigen tests and ...

Compared to the firm's previous PGx offering, the new service is somewhat smaller in terms of content and better supported by ...

Auditors said that independent diagnostic labs should be subject to emergency planning rules similar to those already required for various other healthcare providers.